Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05453721
Other study ID # NFTS-1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date August 4, 2022
Est. completion date December 31, 2027

Study information

Verified date September 2023
Source The First Affiliated Hospital of Nanchang University
Contact Jian Tang, M.D., Ph.D
Phone +8615270901713
Email tangjianku@yeah.net
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a multi-center, prospective, randomized controlled clinical trial. The purpose is to compare the difference of indocyanine green fluorescence imaging method and modified inflation-deflation method in identifying intersegmental plane in segmentectomy, and provide high-level evidence for the selection of intersegmental plane identification method in early NSCLC segmental resection.


Description:

In patients with early-stage lung cancer, segmentectomy has comparable long-term survival results compared with conventional lobectomy, but patients have a higher postoperative quality of life because more lung tissue is preserved. Segmentectomy is based on accurate anatomy, and the identification of intersegmental plane is one of the keys to accurate anatomy of segmentectomy. At present, differential ventilation and differential colorimetry are clinically used to cause the difference between the target segment and the adjacent lung segment to identify intersegmental plane, which both have advantages and disadvantages. Clinical consensus on the best method for intersegmental plane identification has not been formed. This study is a multi-center, prospective, randomized controlled clinical trial. The study plans to enroll 272 patients with peripheral stage I NSCLC with tumor diameter ≤2cm and consolidation tumor rate <1. Eligible patients will be randomly divided into the experimental group (indocyanine green fluorescence imaging method) or control group (modified inflation-deflation method) at a ratio of 1:1. This study is expected to compare the difference of indocyanine green fluorescence imaging method and modified inflation-deflation method in identifying intersegmental plane in segmentectomy, and provide high-level evidence for the selection of intersegmental plane identification method in early NSCLC segmentectomy.


Recruitment information / eligibility

Status Recruiting
Enrollment 272
Est. completion date December 31, 2027
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Aged 18 to 80 years old; 2. According to the surgical standards of the Eighth edition of People's Medical Publishing House, patients whose blood pressure was under 160/100mmHg and blood glucose was under 5.6-11.2mmol /L with normal functions of major organs such as heart, lung, liver and kidney before surgery are included. The main criteria are as follows: i. Cardiac function examination indicated Goldman index grade 1-2; ii. Pulmonary function examination suggested postoperative predicted FEV1=40% and DLCO=40%; iii. Total bilirubin =1.5 times the upper limit of normal; iv. Alanine aminotransferase and aspartate aminotransferase =2.5 times the upper limit of normal value; v. Creatinine =1.25 times the upper limit of normal value and creatinine clearance =60ml/min; 3. The center of the lesion is located in the other lobes except the middle lobe, and in the middle and outer third of the lung; 4. The maximum diameter of the tumor was not more than 2cm on TLC(Thin layer CT) scan and the clinical stage was cT1a-1bN0M0(according to AJCC staging criteria, eighth edition); 5. Consolidation tumor rate <1; 6. ECOG PSscore 0-1; 7. All relevant examinations should be completed within 28 days before surgery; 8. Patients who understand the study and have signed informed consent. Exclusion Criteria: 1. Patient with a history of iodine or indocyanine green allergy; 2. Patient who had received antitumor therapy (radiotherapy, chemotherapy, targeted therapy, immunotherapy) prior to surgery; 3. Patient with a history of other malignancies; 4. Patient with secondary primary cancer at enrollment; 5. Small cell lung cancer; 6. Prior history of unilateral thoracotomy; 7. Woman in pregnant or breastfeeding period; 8. Patient with interstitial pneumonia, pulmonary fibrosis or severe emphysema; 9. An active bacterial or fungal infection that is difficult to control; 10. Severe mental illness; 11. History of severe heart disease , heart failure , myocardial infarction or angina pectoris within the last 6 months; 12. patient that researcher considers inappropriate to participate in this study.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Indocyanine green fluorescence imaging method
Using indocyanine green fluorescence imaging method to identify intersegmental plane in segmentectomy
Modified inflation-deflation method
Using modified inflation-deflation method to identify intersegmental plane in segmentectomy

Locations

Country Name City State
China The First Affiliated Hospital of Nanchang University Nanchang Jiangxi

Sponsors (10)

Lead Sponsor Collaborator
The First Affiliated Hospital of Nanchang University Dazhou Central Hospital, First Affiliated Hospital of Gannan Medical University, Fuzhou Pulmonary Hospital of Fujian, Guangdong Provincial People's Hospital, Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningde Municipal Hospital of Ningde Normal University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Wuhan Union Hospital, China, Zhejiang Provincial People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Coincidence rate of intersegmental plane identification The shortest distance between the nodule and the cutting edge in all directions in postoperative pathological specimens versus distances measured in preoperative 3D reconstruction in same directions Within 14 days after surgery
Primary Success rate of intersegmental plane identification Successful intraoperative appearance of the intersegmental plane is considered a success During the operation
Secondary Intersegment plane identification time Indocyanine green injection/start of ventilation to the first observed intersegment plane appearance During the surgery
Secondary Surgery time Time from the beginning to the end of the surgery During the surgery
Secondary Intraoperatve blood loss Blood loss during the surgery During the surgery
Secondary Postoperative blood loss Blood loss after the surgery Postoperative in-hospital stay up to 30 days
Secondary Postoperative air leakage rate Air leakage after the surgery Postoperative in-hospital stay up to 30 days
Secondary Postoperative air leakage time time of air leakage after the surgery Postoperative in-hospital stay up to 30 days
Secondary Preoperative pulmonary function FEV1.0(forced expiratory volume in 1.0 s) 1 week before the surgery
Secondary Preoperative pulmonary function FVC(forced vital capacity) 1 week before the surgery
Secondary Postoperative pulmonary function FEV1.0(forced expiratory volume in 1.0 s) 6/12 months after surgery
Secondary Postoperative pulmonary function FVC(forced vital capacity) 6/12 months after surgery
Secondary Quality of life(EORTCQLQ-C30) Quality of life Scale 6/12 months after surgery
Secondary Adverse event rate According to CTCAE-V5.0 Through study completion, an average of 2 year
Secondary Adverse event level According to CTCAE-V5.0 Through study completion, an average of 2 year
Secondary Surgical complication According to Clavien-Dindo grading system Postoperative in-hospital stay up to 30 days
Secondary Postoperative 30-day mortality Deaths occurring within 30 days after surgery Within 30 days after surgery
Secondary Postoperative 90-day mortality Deaths occurring within 90 days after surgery Within 90 days after surgery
Secondary Reoperation rate The percentage of patients who need a second operation Within 30 days after surgery
Secondary Number of stapler nail bin used for cutting Number of stapler nail bin used for cutting During the surgery
Secondary R0 resection rate Negative surgical margin under the microscope Within 14 days after surgery
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05451173 - Combining ICI With SBRT or HypoFrx-RT for ES NSCLC Phase 1/Phase 2
Active, not recruiting NCT03603002 - Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer N/A
Completed NCT04342377 - The Canada Lymph Node Score Project: A Crossover Trial Phase 3
Recruiting NCT05097417 - Traditional Chinese Medicine Combined With Thermal and Cold Ablation for Early-stage Lung Cancer N/A
Recruiting NCT06341387 - Volatolomic and Proteomic Profile for Early Diagnosis of Lung Cancer
Completed NCT01991418 - Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC) N/A
Completed NCT03216551 - Mediastinal Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC (ECTOP-1003)
Recruiting NCT03172156 - ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS N/A
Withdrawn NCT03431415 - Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer N/A
Recruiting NCT04716946 - Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy Phase 2
Withdrawn NCT03029871 - Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer Phase 1
Active, not recruiting NCT06180239 - Segmentectomy vs Lobectomy
Active, not recruiting NCT03383302 - SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects Phase 1/Phase 2
Completed NCT04271384 - Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer Phase 2
Recruiting NCT02622581 - Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Not yet recruiting NCT02011997 - Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Phase 3
Active, not recruiting NCT01795521 - LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC Phase 2
Recruiting NCT04944173 - SCION: SABR and Checkpoint Inhibition Of NSCLC Phase 2
Recruiting NCT04585477 - Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) Phase 2